Identity on this record
Chemical name: Tirzepatide.
Common synonyms: LY3298176, dual GIP/GLP-1 receptor agonist peptide.
CAS number: 2023788-19-2 (registry entry).
Molecular formula: C225H348N48O68.
Molecular weight: 4813.53 g/mol.
Appearance: White to off-white lyophilised powder.
Catalog strength: 30 mg vial.
Those identifiers describe Tirzepatide as a substance. They do not describe a particular vial. The vial is identified by the name, the nominal fill, and the lot number on its label, checked against the published certificate.
What the catalogue actually sells
Tirzepatide 30mg is the 30 mg lyophilized unit, listed at AED 599 before VAT. The product record stores that sealed unit at 2–8 °C · protect from light.
Prices are merchandise prices in AED, exclusive of VAT. VAT is added at checkout. A price on this summary is the figure on the product record for Tirzepatide, not a delivered-cost quote.
Lots and certificates
Lot VL-TIRZ-20260801 is the catalogue certificate for Tirzepatide 30mg. Read it on Tirzepatide 30mg certificate and match the vial in batch verification. A certificate for a different strength, or for a blend that merely contains the same name, does not release this unit.
How the compound record describes the literature
Developed as LY3298176; clinical literature describes pharmaceutical products under specific indications. VaultLabs research-grade material is a separate laboratory reference supply with independent lot documentation.
Topics named on the Tirzepatide record, as literature context rather than as outcomes VaultLabs claims: Dual incretin receptor pharmacology; Comparative GLP-1 / GIP agonist assays; Analytical characterisation of large incretin peptides.
That is context for identifying Tirzepatide. It is not a claim that a vial produces a result in a person, an animal, or a study VaultLabs has not published. VaultLabs does not provide dosage, administration, study-design, or medical guidance.
Points the monograph already states
Points already written on the Tirzepatide monograph, so a reader can check them against that page:
Dual GIP/GLP-1 receptor agonist; literature CAS registry number 2023788-19-2.
Development designation LY3298176; large synthetic peptide requiring careful chromatographic handling.
Catalog presentation is 30 mg lyophilised research material with independent lot documentation.
Approved pharmaceutical products in some jurisdictions are not the VaultLabs research SKU.
Not for human or veterinary use.
Dispatch and the research-use boundary
VaultLabs dispatches Tirzepatide from Dubai. Orders leave fulfillment within 24 hours, 7 days a week. Standard delivery is AED 35 to every emirate, and delivery is free when the post-discount merchandise subtotal is AED 500 or more. Checkout shows the fee for the address entered. All VaultLabs products are supplied strictly for laboratory and research use only. They are not intended for human consumption, medical use, personal use, or diagnostic use. VaultLabs does not provide dosage, administration, study-design, or medical guidance.
The full narrative record is the Tirzepatide compound monograph. Handling of the sealed unit is the Tirzepatide storage guide. Questions are collected on the Tirzepatide FAQ. How it differs from neighbouring records is the Tirzepatide comparison.